GlassScriptPhysician profile
David P Mcgarry
NPI 1093135188
$66,240.76
in general payments reported to CMS, 2019-2025
33 companies · $9,443 in 2025
The $9,443 reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $209 · 2021: $587 · 2022: $15K · 2023: $28K · 2024: $13K · 2025: $9,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $6,496 · Consulting Fee: $1,478 · Travel and Lodging: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,975.00 |
| Food and Beverage | $6,495.99 |
| Consulting Fee | $1,477.86 |
| Travel and Lodging | $394.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $40,020.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $19,850.49 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genentech USA, INC. | $1,654.90 | 2021-2025 | Xolair |
| Biocryst US Sales Co., LLC | $648.34 | 2022-2025 | Orladeyo |
| Amgen INC. | $647.85 | 2021-2025 | Tezspire, Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $625.51 | 2022-2025 | Cuvitru, Hyqvia, Takhzyro |
| Novartis Pharmaceuticals Corporation | $528.88 | 2019-2025 | |
| Pharming Healthcare, INC. | $326.58 | 2021-2025 | Ruconest |
| Csl Behring | $296.40 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Blueprint Medicines Corporation | $233.82 | 2022-2025 | Ayvakit |
| Horizon Therapeutics Plc | $233.19 | 2019-2023 | Actimmune |
| Regeneron Healthcare Solutions, INC. | $164.18 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $132.56 | 2021-2024 | Prolastin-C Liquid, Gamunex-C |
| Adma Biomanufacturing LLC | $127.86 | 2023-2024 | |
| Pfizer INC. | $86.09 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.75 | 2023 | Spiriva Respimat |
| Becton, Dickinson and Company | $50.00 | 2023 | Bd Safetyglide |
| Ionis Pharmaceuticals, INC. | $46.85 | 2025 | Dawnzera |
| Ars Pharmaceuticals Operations, INC. | $45.75 | 2025 | Neffy |
| Leo Pharma INC. | $44.81 | 2022-2023 | Adbry |
| Alk-Abello, INC | $43.54 | 2023-2025 | Pre-Pen, Alternaria Tenuis, Timothy, Standardized |
| Lilly USA, LLC | $43.44 | 2025 | Ebglyss |
| Verona Pharma, INC. | $35.64 | 2025 | Ohtuvayre |
| Tersera Therapeutics LLC | $31.69 | 2024 | Quzyttir |
| Cycle Pharmaceuticals INC | $30.31 | 2025 | Sajazir |
| Paratek Pharmaceuticals, INC. | $28.82 | 2025 | Xhance |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Shire North American Group INC | $25.23 | 2019 | |
| Octapharma USA, INC. | $22.27 | 2024 | Panzyga |
| X4 Pharmaceuticals, INC. | $20.55 | 2025 | Xolremdi |
| Phadia US INC. | $19.52 | 2021 | |
| Galderma Laboratories, L.P. | $16.68 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcgarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.